Summit Therapeutics (SMMT) Operating Income (2016 - 2024)
Historic Operating Income for Summit Therapeutics (SMMT) over the last 8 years, with Q4 2024 value amounting to -$65.6 million.
- Summit Therapeutics' Operating Income fell 8120.41% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$180.7 million, marking a year-over-year decrease of 9234.84%. This contributed to the annual value of -$226.0 million for FY2024, which is 6292.99% up from last year.
- As of Q4 2024, Summit Therapeutics' Operating Income stood at -$65.6 million, which was down 8120.41% from -$58.4 million recorded in Q3 2024.
- Summit Therapeutics' Operating Income's 5-year high stood at -$7.6 million during Q1 2020, with a 5-year trough of -$65.6 million in Q4 2024.
- Its 4-year average for Operating Income is -$32.2 million, with a median of -$20.5 million in 2023.
- Its Operating Income has fluctuated over the past 5 years, first soared by 448.54% in 2020, then crashed by 18488.19% in 2024.
- Summit Therapeutics' Operating Income (Quarter) stood at -$7.6 million in 2020, then crashed by 167.13% to -$20.3 million in 2022, then plummeted by 78.38% to -$36.2 million in 2023, then plummeted by 81.2% to -$65.6 million in 2024.
- Its Operating Income was -$65.6 million in Q4 2024, compared to -$58.4 million in Q3 2024 and -$36.2 million in Q4 2023.